Research Article
Cross-Disease Innate Gene Signature: Emerging Diversity and Abundance in RA Comparing to SLE and SSc
Table 1
Demographic and clinical characteristics of enrolled patients.
| | RA () | SLE () | SSc () |
| | Female/male | 26/10 | 24/4 | 15/7 | | Age (years) mean (min-max) | 57.5 (39-80) | 40.1 (19-67) | 58.0 (38-77) | | Duration of the disease (years) mean (min-max) | 18.1 (9-50) | 10.0 (1-20) | 5.4 (0-21) | | Medications (% ()) | | | | | Steroids | 89 (32) | 82 (23) | 96 (21) | | NSAIDs | 78 (28) | 14 (4) | 0 (0) | | Methotrexate | 83 (30) | 14 (4) | 9 (2) | | Other DMARDs | 36 (13) | 100 (28) | 73 (16) | | Biologics | 39 (14) | 0 (0) | 0 (0) | | Relative white blood count (%) | | | | | Lymphocytes (mean (95% CI)) | 24.9 (20.5-29.3) | 22.9 (18.5-27.3) | 21.4 (17.5-25.4) | | Neutrophils (mean (95% CI)) | 62.9 (57.9-67.9) | 67.1 (61.6-72.6) | 67.3 (62.5-72.2) | | Monocytes (mean (95% CI)) | 8.9 (7.9-9.9) | 8.5 (7.1-9.9) | 9.2 (7.9-10.4) |
|
|
NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs; CI: confidence interval. Other DMARDs taken were hydroxychloroquine (RA/SLE/SSc; ), leflunomide (8/0/0), sulfasalazine (2/0/0), azathioprine (0/8/12), mycophenolate mofetil (0/6/0), cyclophosphamide (0/3/3), and cyclosporine (0/1/1). |
